Cargando…

Daratumumab in dialysis-dependent multiple myeloma

Detalles Bibliográficos
Autores principales:	Jeyaraman, Preethi, Bhasin, Alka, Dayal, Nitin, Pathak, Sangeeta, Naithani, Rahul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106121/ https://www.ncbi.nlm.nih.gov/pubmed/32269978 http://dx.doi.org/10.5045/br.2020.55.1.65

Ejemplares similares

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
por: Husian, Sadik, et al.
Publicado: (2021)

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
por: Saburi, Masuho, et al.
Publicado: (2020)

Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma
por: Liu, Shanshan, et al.
Publicado: (2023)

Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma
por: Naithani, Rahul, et al.
Publicado: (2020)

Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
por: Nakamura, Fumihiko, et al.
Publicado: (2019)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
por: Zajec, Marina, et al.
Publicado: (2020)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second
por: Kim, Jin-Hyo, et al.
Publicado: (2022)

Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma
por: Liberatore, Carmine, et al.
Publicado: (2023)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients
por: Lemonakis, Konstantinos, et al.
Publicado: (2022)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
por: Choudhry, Priya, et al.
Publicado: (2019)

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
por: van der Veer, M S, et al.
Publicado: (2011)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
por: Hulin, Cyrille, et al.
Publicado: (2021)

Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?
por: Kalis, Joseph A.
Publicado: (2017)

Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
por: Barbieri, Emiliano, et al.
Publicado: (2022)

Short Term Renal Outcome of Bortezomib Based Therapy in Patients with Multiple Myeloma Requiring Dialysis
por: Pandey, Alok Kumar, et al.
Publicado: (2020)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2018)

New developments in the treatment of multiple myeloma – clinical utility of daratumumab
por: McEllistrim, Cian, et al.
Publicado: (2017)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab
por: Meng, Jie, et al.
Publicado: (2022)

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
por: Shen, Fei, et al.
Publicado: (2022)

Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma
por: Wang, Pei, et al.
Publicado: (2023)

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
por: Zamanillo, Irene, et al.
Publicado: (2023)

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
por: King, Tracy, et al.
Publicado: (2018)

Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia
por: Crickx, Etienne, et al.
Publicado: (2021)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014
por: Laforet, M, et al.
Publicado: (2016)

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
por: Dima, Danai, et al.
Publicado: (2020)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Use of daratumumab in high risk multiple myeloma: A meta‐analysis
por: Premkumar, Vikram, et al.
Publicado: (2020)

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
por: Krejcik, Jakub, et al.
Publicado: (2018)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Retracted: Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab
por: Oncology, Journal of
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7q212sg0u4u1o0atgssbhntvjl